CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
URSODIOL	IM	*USP36–NF31*	5520	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First*	Line 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	PURITIES/*Organic Impurities*/*Procedure*						*Supplement to USP37–NF32*	*Sample solution*: Change Tablets, equivalent to about 25 mg of ursodiol, to: Tablets, equivalent to about 250 mg of ursodiol,
SORBITAN MONOPALMITATE	IDENTIFICATION/*A.*	*USP36–NF31*	2213	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Sample*: Change 1 g of the residue obtained in the *Assay for Fatty Acids* to: Residue obtained in the *Assay for Fatty Acids* AND Line 2 of *Acceptance criteria*: Change 210–225 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								210–225 on 1-g sample
BETHANECHOL CHLORIDE	IMPURITIES/*Heavy Metals, Method 1 <231>*	*Second Supplement to USP36–NF31*	6568	27-Sep-2013	1-Oct-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Test preparation*: Change Bethacholine Chloride to: Bethanechol Chloride
POWDERED STINGING NETTLE	COMPOSITION/*Content of Total Amino Acids*	*USP36–NF31*	1606	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Reagent solution*: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
MEPROBAMATE TABLETS	ASSAY/*Procedure*	*First Supplement to USP36–NF31*	6015	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 4 of *Standard solution*: Change Dissolve in 30% of the final flask

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volume, and dilute with water to volume. to: Dissolve in 30% of the final flask volume of acetonitrile, and dilute with water to volume.
BETAMETHASONE SODIUM PHOSPHATE	*Identification/B. Thin-Layer Chromatographic Identification Test <201>*	*USP36–NF31*	2645	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Test solution*: Change 1 mg per mL. to: 1 mg per mL in methanol.
DACARBAZINE FOR INJECTION	*USP Reference standards <11>*	*USP36–NF31*	3137	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 3 of USP Dacarbazine Related Compound B RS: Change $C_4H_3N_5O$ 137.10 to: $C_4H_3N_5O \cdot H_2O$ 155.12
EDETATE DISODIUM	ASSAY/ *Procedure*	*USP36–NF31*	3370	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 5: Delete *Titrimetric system* (See *Titrimetry*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								<541>.) *Mode*: Direct titration *Titrant*: 0.1 N sodium hydroxide VS *Endpoint detection*: Visual
LAMOTRIGINE TABLETS	PERFORMANCE TESTS/ *Dissolution* <711>/*Test 1*	*USP36–NF31*	4056	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 3 of *Standard solution*: Change 0.028 µg/mL to: 0.028 mg/mL
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*/*Table 2*	*USP36–NF31*	5438	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Footnote c: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present). to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual unspecified impurity if present). AND Footnote d: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydrochloride (identified and reported as an individual unspecified impurity if present).
PURIFIED GYMNEMA EXTRACT	COMPOSITION /*Content of Gymnemic Acids*	*First Supplement to USP36–NF31*	5884	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Acceptance criteria*: Change 90%–110% of the labeled amount to: 90.0%–110.0% of the labeled amount on the dried basis
SODIUM HYDROXIDE	ASSAY/ *Procedure*	*USP36–NF31*	2203	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 11 of *Analysis*: Change = volume of *Titrant* consumed by the *Sample* to the first endpoint (mL) to: = volume of *Titrant* consumed by

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Sample* to the second endpoint (mL)
CLARITHROMYCIN FOR ORAL SUSPENSION	ASSAY/ *Procedure*	*USP36–NF31*	3018	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Change the subsection head *Buffer*: to: *Buffer A*: AND After the *Buffer A* subsection: Add *Buffer B*: 0.067 M dibasic potassium phosphate AND Line 1 of *Mobile phase*: Change Methanol and *Buffer* to: Methanol and *Buffer A* AND Line 4 of *Sample stock solution*: Change with the aid of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								330 mL of *Buffer*, to a 1000-mL volumetric flask containing 50 mL of *Buffer*. to: with the aid of 330 mL of *Buffer B*, to a 1000-mL volumetric flask containing 50 mL of *Buffer B*.
DIPHENHYDRAMINE HYDROCHLORIDE INJECTION	*Assay*	*USP36–NF31*	3276	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *System suitability solution*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diphenhydramine Hydrochloride*. to: *Mobile*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phase—Prepare a solution of acetonitrile, water, and triethylamine (50: 50: 0.5), adjust with glacial acetic acid to a pH of 6.5, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation*—Dissolve an accurately weighed quantity of USP Diphenhydramine Hydrochloride RS in water to obtain a solution having a known

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								concentration of about 0.5 mg per mL. AND After the *Assay preparation* subsection: Add *System suitability solution* —Dissolve about 5 mg of benzophenone in 5 mL of acetonitrile, dilute with water to 100 mL, and mix. Transfer 1.0 mL of this solution and 5 mg of diphenhydramine hydrochloride to a 10-mL volumetric flask, dilute with water to volume, and mix. *Chromatographic system* (see *Chromatograph*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L10. The flow rate is about 1 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*; the resolution, *R*, between the benzophenone and diphenhydramine peaks is not less than 2.0. Chromatograph replicate injections of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard preparation, and record the peak responses as directed for *Procedure*; the relative standard deviation is not more than 2.0%, and the tailing factor for the diphenhydramine hydrochloride peak is not more than 2.0. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diphenhydramine Hydrochloride*. to: Separately inject equal

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volumes, about 10 ?L, of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
FEXOFENADINE HYDROCHLORIDE TABLETS	ASSAY/ *Procedure*	*USP36–NF31*	3576	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 6 of *Sample stock solution*: Change (equivalent to 80% of the total flask volume) to: (sufficient to fill the flask to 80% of its volume)
NIFEDIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 4/Instrumental*	*USP36–NF31*	4509	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Cell*: Change 0.5 cm to: 1 cm

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	conditions							
GYMNEMA	IDENTIFICATION/*B. Thin-Layer Chromatography/ Chromatographic system*	*First Supplement to USP36–NF31*	5880	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Adsorbent*: Change 5m to: 5 µm
POWDERED STINGING NETTLE EXTRACT	COMPOSITION/*Content of Total Amino Acids*	*USP36–NF31*	1608	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Reagent solution*: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
OXCARBAZEPINE	IMPURITIES/*Organic Impurities, Procedure 1*	*First Supplement to USP36–NF31*	6035	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Row 4 of Column 1 of *Table 1*: Change Dibenzazepinone[b] to: Oxcarbazepine related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound E AND Delete footnote b AND Reletter the following footnotes in both the table and footnote definitions: c to b d to c e to d
CALCIUM CARBONATE	IMPURITIES	*USP36–NF31*	2747	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Acceptance criteria* in *Limit of Fluoride*: Change 50 ppm to: NMT 50 ppm AND Line 1 of *Acceptance criteria* in *Mercury, Method IIa <261>*: Change 0.5 ppm to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CRYOPRESERVED HUMAN FIBROBLAST-DERIVED DERMAL SUBSTITUTE	*Total collagen content*	*USP36–NF31*	3155	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	NMT 0.5 ppm Line 7 of *Collagen calibration standards*: Change by adding 25 mL, 50 mL, 100 mL, and 200 mL, to: by adding 25 ?L, 50 ?L, 100 ?L, and 200 ?L,
EDETATE DISODIUM	ASSAY/ *Procedure*	*USP36–NF31*	3370	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 16 of *Analysis*: Change Calculate the percentage of edetate disodium to: Calculate the weight of edetate disodium AND Line 19 of *Analysis*: Change Result = (*V*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_T/V_U$) × *W* × (M_{r1}/M_{r2}) × 100 to: Result = (V_T/V_U) × *W* × (M_{r1}/M_{r2})
LEVOFLOXACIN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP36–NF31*	4099	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of USP Levofloxacin Related Compound A RS: Change (*S*)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*][1,4-benzoxazine-6-carbocylic acid. to: (*S*)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-p yrido [1,2,3-*de*][1,4]benzoxazi ne-6-carboxylic acid. AND Line 2 of USP Levofloxacin Related Compound B RS: Change (*S*)-9,10-Difluoro- 3-methyl-7-oxo- 2, 3-di hydro-7*H* -p yrido [1,2,3-*de*][1,4-benzoxazi ne-6-carbocylic acid. to: (*S*)-9,10-Difluoro- 3-methyl-7-oxo- 2, 3-di hydro-7*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-p yrido [1,2,3-*de*][1,4]benzoxazine-6-carboxylic acid.
VENLAFAXINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP36–NF31*	5551	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. $C_{16}H_{25}NO_2$ 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl) cyclohexanol hydrochloride. $C_{16}H_{25}NO_2 \cdot HCl$ 299.84
STINGING NETTLE	COMPOSITION /*Content of Total Amino Acids*	*USP36–NF31*	1604	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Reagent solution*: Change Solution

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,
GENTAMICIN SULFATE	IM PURITIES/*Limit of Methanol*	*First Supplement to USP36–NF31*	5990	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 11 of *Analysis*: Change Result = $(R_U/R_S) \times (C_S/C_U) \times D \times F \times 100$ to: Result = $(R_U/R_S) \times (C_S/C_U) \times D \times F$ AND Line 18 of *Analysis*: Change C_S = percentage of methanol in the *Standard solution* (% v/v) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_S = percentage of methanol in the *Standard solution* AND Line 23 of *Analysis*: Change *F* = conversion factor, 0.001 g/mg to: *F* = conversion factor, 1000 mg/g
AMOXICILLIN	IM PUR ITIES/*Organic Impuri ties*/*Procedure*	*USP36–NF31*	2477	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Acceptance criteria*: Change [Note—The reporting limit is 0.03% of the amoxicillin peak from the *Standard solution*.] to: [Note—The reporting limit is 0.03 times the amoxicillin peak

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								from the *Standard solution*.]
CLARITHROMYCIN EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 4*	*USP36–NF31*	3019	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Standard solution*: Change and *Medium* (96:4). to: and *Medium* (4:96).
DIPHENHYDRAMINE HYDROCHLORIDE ORAL SOLUTION	*Assay*	*USP36–NF31*	3277	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *System suitability solution*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diphenhydramine Hydrochloride*. to: *Mobile phase*—Prepare a solution of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acetonitrile, water, and triethylamine (50: 50: 0.5), adjust with glacial acetic acid to a pH of 6.5, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation* —Dissolve an accurately weighed quantity of USP Diphenhydramine Hydrochloride RS in water to obtain a solution having a known concentration of about 0.5 mg

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								per mL. AND After the *Assay preparation* subsection: Add *System suitability solution* —Dissolve about 5 mg of benzophenone in 5 mL of acetonitrile, dilute with water to 100 mL, and mix. Transfer 1.0 mL of this solution and 5 mg of diphenhydramine hydrochloride to a 10-mL volumetric flask, dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L10. The flow rate is about 1 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*; the resolution, *R*, between the benzophenone and diphenhydramine peaks is not less than 2.0. Chromatograph replicate injections of the *Standard preparation*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and record the peak responses as directed for *Procedure*; the relative standard deviation is not more than 2.0%, and the tailing factor for the diphenhydramine hydrochloride peak is not more than 2.0. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diphenhydramine Hydrochloride*. to: Separately inject equal volumes, about 10 ?L, of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard preparation and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
FLUPHENAZINE DECANOATE INJECTION	*Assay*	*USP36–NF31*	3639	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 11 of *Standard preparation*: Delete (1:5) AND Line 8 of *Assay preparation*: Delete (1:5)
OLMESARTAN MEDOXOMIL	IMPURITIES/*Organic Impurities/Impurity Table*	*USP36–NF31*	4570	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Footnote d: Change ((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2′-(1-trityl-1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-tetrazol-5-yl)biphenyl-4-yl)methyl)-1*H*-imidazole-5-carboxylate. to: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(2-trityl-1*H*-tetrazol-5-yl)biphenyl-4-yl)methyl)-1*H*-imidazole-5-carboxylate.
POWDERED GYMNEMA	IDENTIFICATION/*B*. *Thin-Layer Chromatography*/*Chromatographic system*	*First Supplement to USP36–NF31*	5883	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Adsorbent*: Change 5m to: 5 µm
GLYCERYL DISTEARATE	ASSAY/*Procedure*/*Chromatographic system*	*USP36–NF31*	2029	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Column temperature*: Change *Column temperature*: 40°

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Temperatures* *Detector*: 40° *Column*: 40°
OXCARBAZEPINE	IMPURITIES/*Organic Impurities, Procedure 2*	*First Supplement to USP36–NF31*	6035	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Row 9 of Column 1 of *Table 3*: Change Oxcarbazepine related compound E[g] to: Oxcarbazepine related compound E AND Delete footnote g
CEFDINIR CAPSULES	IMPURITIES/*Organic Impurities*/*Table 2*	*USP36–NF31*	2850	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Row 16 of Column 1: Change Cefdinir impurity 2[e] to: Cefdinir impurity 2[f] AND Row 21 of Column 1: Change Cefdinir impurity

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3[e] to: Cefdinir impurity 3[f]
DIPHENHYDRAMINE HYDROCHLORIDE CAPSULES	*Assay*	*USP36–NF31*	3276	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *System suitability solution*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diphenhydramine Hydrochloride*. to: *Mobile phase*—Prepare a solution of acetonitrile, water, and triethylamine (50: 50: 0.5), adjust with glacial acetic acid to a pH of 6.5, filter, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation*—Dissolve an accurately weighed quantity of USP Diphenhydramine Hydrochloride RS in water to obtain a solution having a known concentration of about 0.5 mg per mL. AND After the *Assay preparation* subsection: Add *System suitability solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								—Dissolve about 5 mg of benzophenone in 5 mL of acetonitrile, dilute with water to 100 mL, and mix. Transfer 1.0 mL of this solution and 5 mg of diphenhydramine hydrochloride to a 10-mL volumetric flask, dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L10.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								The flow rate is about 1 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*; the resolution, *R*, between the benzophenone and diphenhydramine peaks is not less than 2.0. Chromatograph replicate injections of the *Standard preparation*, and record the peak responses as directed for *Procedure*; the relative standard deviation is not more than

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2.0%, and the tailing factor for the diphenhydramine hydrochloride peak is not more than 2.0. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diphenhydramine Hydrochloride*. to: Separately inject equal volumes, about 10 ?L, of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and measure the responses for the major peaks.
FELBAMATE TABLETS	IMPURITIES/*Organic Impurities*/*System suitability*/*Suitability requirements*	*USP36–NF31*	3537	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Resolution*: Change NMT 2 to: NLT 2
MOXIFLOXACIN OPHTHALMIC SOLUTION	*Related compounds*	*USP36–NF31*	4414	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Row 1 of Column 3 of *Table 2*: Change Relative Retention Time vs. Moxifloxacin to: Relative Retention vs. Moxifloxacin AND Row 1 of Column 3 of *Table 3*: Change Relative Retention Time vs. Moxifloxacin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Relative Retention vs. Moxifloxacin
VENLAFAXINE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP36–NF31*	5554	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. $C_{16}H_{25}NO_2$ 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl) cyclohexanol hydrochloride. $C_{16}H_{25}NO_2 \cdot HCl$ 299.84
ALBUTEROL SULFATE	*Chromatographic purity*	*USP36–NF31*	2352	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1: Change It meets the requirements of the test for *Chromatographic purity* under *Albuterol*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the *Standard solution* and the *Test solution*. to: It meets the requirements of the test for *Organic Impurities* under *Albuterol*, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the *Standard solution* and the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution.
MINOCYCLINE HYDROCHLORIDE CAPSULES	*Assay*	*USP36–NF31*	4375	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *Resolution solution*, and *Chromatographic system* —Proceed as directed in the *Assay* under *Minocycline Hydrochloride*. to: *Mobile phase*—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								pass through a filter of 0.5-µm or finer pore size. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation*—Dissolve an accurately weighed quantity of USP Minocycline Hydrochloride RS in water to obtain a solution having a known concentration of about 500 µg of minocycline ($C_{23}H_{27}N_3O_7$) per mL. Use this solution within 3 hours. *Resolution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution—Transfer 10 mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180 minutes, and allow to cool. Dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm ×

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the capacity factor, *k´*, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								replicate injections is not more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, *R*, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of *Procedure*: Change Proceed as directed for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Procedure in the *Assay* under *Minocycline Hydrochloride*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
NIFEDIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP36–NF31*	4509	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Solution A*: Change Dissolve 330.9 mg of sodium phosphate to: Dissolve 330.9 g of dibasic sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE FOR EFFERVESCENT ORAL SOLUTION	*Assay for potassium*	*USP36–NF31*	4834	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	phosphate Line 2: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								instead of *Sample solution*.
POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS	*Dissolution <711>*	*USP36–NF31*	4841	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 5: Change *Potassium stock solution*— to: *Standard stock solution*— AND Line 7: Change Prepare as directed for *Standard preparations* to: Prepare as directed for *Standard solutions* AND Line 7 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								conditions and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*.
THIMEROSAL TOPICAL AEROSOL	SPECIFIC TESTS/*Alcohol Determination, Method II <611>*	*USP36–NF31*	5369	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 4 of *Analysis*: Change Determine the alcohol content of the sample thus prepared by the *Gas–Liquid Chromatographic Method* (see *Method II* in *Alcohol Determination* <611>, using methyl ethyl ketone as the internal standard in place of acetone. to: Determine the alcohol content of the sample

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								thus prepared by the *Gas Chromatographic Method* (see *Method II* in *Alcohol Determination* <611>), using methyl ethyl ketone as the internal standard in place of acetonitrile.
NORTRIPTYLINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*First Supplement to USP36–NF31*	6027	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Acceptance criteria*: Change *Standard solution* to: *Sample solution*
CARAWAY OIL	DEFINITION	*USP36–NF31*	1924	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3: Change It contains NMT 50.0% of *d*-carvone ($C_{10}H_{14}O$). to: It contains NLT 50.0% of *d*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-carvone ($C_{10}H_{14}O$).
FOSPHENYTOIN SODIUM INJECTION	*USP Reference standards <11>*	*USP36–NF31*	3680	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 6: Change $C_{14}H_{15}NO_2$ to: $C_{14}H_{13}NO_2$
MINOCYCLINE HYDROCHLORIDE TABLETS	*Assay*	*USP36–NF31*	4378	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *Resolution solution*, and *Chromatographic system* —Proceed as directed in the *Assay* under *Minocycline Hydrochloride*. to: *Mobile phase*—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer pore size. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation*—Dissolve an accurately weighed quantity of USP Minocycline Hydrochloride RS in water to obtain a solution having a known concentration of about 500 µg of minocycline

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								($C_{23}H_{27}N_3O_7$) per mL. Use this solution within 3 hours. *Resolution solution* —Transfer 10 mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180 minutes, and allow to cool. Dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the capacity factor, *k´*, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, *R*, between epiminocycline and minocycline is not less than 4.6. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Minocycline Hydrochloride*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
PENTAZOCINE INJECTION	*Chemical Information*	*USP36–NF31*	4734	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1: Remove all chemical information.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- Page 31
- Page 32
- Next page Next ›
- Last page Last »